Skip to content
DataLookout
Menu

NCT04848779

A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

StatusCompleted
PhaseNot specified
SponsorSanofi
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 21 versions: 19 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria revised Show 4 more changesShow less
    • Trial completed
    • Final enrollment: 9 participants (planned 16)
    • Primary and study completion dates changed from estimate of Oct 28, 2026 to Oct 27, 2026
    • Site details revised at 3 of 15 sites
  2. Notable Primary and study completion dates: Mar 30, 2026 to Oct 28, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites revised (15)
    v19
  3. Minor Study sites: 14 to 15v18
  4. Minor Site details revised at 1 of 14 sitesv17
  5. Minor Site details revised at 1 of 14 sitesv16
Show 13 earlier versionsHide 13 earlier versions
  1. Notable Primary and study completion dates: Apr 11, 2025 to Mar 30, 2026
    • Study sites: 13 to 14
    v15
  2. Minor Study sites: 12 to 13v14
  3. Minor Study sites: 9 to 12v13
  4. Minor Primary and study completion dates: Nov 12, 2024 to Apr 11, 2025
    • Secondary endpoints: details revised at 6 of 19 entries
    • Study description revised
    v11
  5. Minor Site details revised at 1 of 9 sitesv10
  6. Minor Study sites: 5 to 9v9
  7. Notable Eligibility criteria revised
    • Interventions: Alglucosidase alfa GZ419829 (Myozyme) (Drug) to Alglucosidase alfa GZ419829 (Drug)
    • Study title shortened, about 1 word
    v8
  8. Minor Study sites: 4 to 5
    • Primary and study completion dates: Nov 11, 2024 to Nov 12, 2024
    v7
  9. Minor Study sites: 3 to 4
    • Primary and study completion dates: Dec 19, 2024 to Nov 11, 2024
    v6
  10. Minor Primary and study completion dates: Oct 2024 to Dec 19, 2024v5
  11. Notable Eligibility criteria expanded, about 3 words
    • Study sites: 2 to 3
    v4
  12. Minor Study sites: 1 to 2
    • Start date changed from estimate of Apr 2021 to Jun 10, 2021
    v3
  13. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of participants alive and free of invasive ventilation at Week 52 of treatment
Timeframe: Week 52

Secondary (19)

Proportion of participants alive and free of invasive ventilation at 12 and 18 months of age
Proportion of participants alive at Week 52 of treatment
Proportion of participants alive at 12 months and 18 months of age
Proportion of participants free of ventilator use and free of supplemental oxygen use at Week 52
Change from baseline to Week 52 in LVM Z score
Show 14 moreShow less
Change from baseline to Week 52 in AIMS score
Change from baseline to Week 52 in body length Z-scores
Change from baseline to Week 52 in body weight Z-scores
Change from baseline to Week 52 in head circumference Z-scores
Change from baseline to Week 52 in body length percentiles
Change from baseline to Week 52 in body weight percentiles
Change from baseline to Week 52 in head circumference percentiles
Change from baseline to Week 52 in urinary Hex4
Number of participants experiencing at least 1 treatment-emergent adverse events (TEAE), including infusion-associated reactions (IAR)
Number of participants with abnormalities in physical examinations
Number of participants with abnormalities in clinical laboratory results
Number of participants with abnormalities in vital signs measurements
Number of participants with abnormalities in 12-lead electrocardiogram (ECG)
Incidence of treatment-emergent antidrug antibodies (ADA)

Arms and interventions

Cohort 1

Drugs: Alglucosidase alfa GZ419829

Sites

15 sites in 9 countries

United States 5, Italy 2, United Kingdom 2, Belgium 1, France 1, Germany 1, Netherlands 1, Spain 1, Taiwan 1